Search Results
Your search for can matches 13758 pages
Showing 3001 - 3050Study Finds That Compared to Urban Residents, Rural Residents Are More Likely to Have Fatalistic Beliefs About Cancer
There is strong evidence showing that avoiding tobacco use, maintaining a healthy diet and weight, and being physically active are effective strategies for reducing cancer risk. In addition, the early detection of certain cancer types through screening has the potential to reduce cancer mortality...
David Cescon, MD, PhD, Comments on the MONALEESA Analyses
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
Risk of Multiple Cancers in Male Carriers of BRCA1 and BRCA2 Gene Mutations
People who carry the BRCA1 or BRCA2 gene mutation have an increased risk of pancreatic, stomach, and prostate cancers, as well as the previously well-known risk of breast and ovarian cancers, according to new research calling for increased testing in male carriers to detect the cancers early. The...
Carolyn Presley, MD, on Dementia in Patients Treated for Thoracic Cancer
Carolyn Presley, MD, of The Ohio State University, discusses the differences between “chemo brain,” cognitive aging, and dementia in patients with thoracic cancer who are in treatment; how to test for impairment; and the interventions that can improve cognitive changes in survivors.
Study Identifies Black Race as Risk Factor for Lymphedema After Axillary Dissection in Women With Breast Cancer
Black women with breast cancer had significantly higher rates of lymphedema after axillary lymph node dissection compared with Hispanic, White, and Asian women in a prospective study of breast cancer–related lymphedema presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). In fact,...
Cancer Has Made Me a Risk-Taker, and That’s Good
In 2017, I was caring for my brother, who was suffering from respiratory failure due to complications from cerebral palsy, and working full-time as a registered nurse. I was feeling overwhelmed and exhausted all the time. I was also losing weight at an alarming rate—more than 70 pounds in just a...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Burundi
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Burundi. The aim of this special feature is to highlight the global cancer burden for various countries of the...
An Adventurous Spirit Led to a Prominent Role in Radiation Oncology for Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO
Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO, founding Chair of the West Virginia University (WVU) Department of Radiation Oncology, was born in Fort Dix, New Jersey. Her father was a military officer, and his various duty posts offered an adventurous childhood for Dr. Jacobson. “One of my...
From the Vietnam War to the Stanford Cancer Institute: The Professional Journey of Quynh-Thu Le, MD
In this installment of the Living a Full Life series, guest editor, Jame Abraham, MD, FACP, spoke with Quynh-Thu Le, MD, Chair of the Department of Radiation Oncology and Co-Director of the Radiation Biology Program of the Stanford Cancer Institute, and one of the Group Chairs of the NRG Oncology...
Project Catalyst: Educating Industry to Help Develop Successful Cancer Therapies
OCE Insights is written by members of the Oncology Center of Excellence (OCE) and the Office of Oncology Diseases (OOD) at the U.S. Food and Drug Administration. In this installment, Jeff Summers, MD, OOD Acting Associate Director for Translational Sciences, and Marc R. Theoret, MD, OCE Deputy...
Promise and Need for More Progress in Treatment of Squamous Cell NSCLC
A greater understanding of the mutational landscape in non–small cell lung cancer (NSCLC) has identified key oncogenes, such as EGFR, ALK, ROS, RET, and BRAF, among others. These discoveries, coupled with the availability of specific targeted small-molecule inhibitors, have transformed the...
ASCO Statement on 50th Anniversary of Signing of National Cancer Act
“Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer. “At the time the bill was signed into law, pioneers in our field had already made substantial discoveries, but we ...
ASCO Unveils New Equity, Diversity, and Inclusion Action Plan
Building on its long history of advancing health equity in cancer care, ASCO recently released “The ASCO Equity, Diversity, and Inclusion (EDI) Action Plan: A Legacy of Commitment, A Future of Promise for Individuals with Cancer.” The plan aims to infuse equity into all of the organization’s...
Health Groups Make Recommendations to Strengthen the U.S. Drug Supply Chain During the Pandemic and Beyond
ASCO—along with the American Medical Association, the American Society of Anesthesiologists, the American Society of Health-System Pharmacists, and the United States Pharmacopeia—released a series of policy and marketplace recommendations to address the significant challenges in our nation’s drug...
BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...
Circadian Timing of Immune Checkpoint Inhibitors: Beyond Good Times and Bad Times
After almost a century of limited efficacy of cancer immunotherapy,1 the breakthrough happened in 2012 with the discovery of immune checkpoint inhibitors,2,3 leading to the 2018 Nobel Prize in Physiology or Medicine for James P. Allison and Tasuku Honjo. Yet about 40% of patients on immune...
Expert Point of View: Jane N. Winter, MD and Christopher R. Flowers, MD, MS
Jane N. Winter, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and the 2022 President of the American Society of Hematology (ASH), and Christopher R. Flowers, MD, MS, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
Expert Point of View: Amy Tiersten, MD and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Better Federal Agency Coordination Is Needed to Accelerate Progress Against Cancer
President Richard M. Nixon signed the National Cancer Act into law on December 23, 1971. The unprecedented legislation granted sweeping authority to the Director of the National Cancer Institute (NCI) to develop a national cancer program that included the NCI, other research institutes, and federal ...
ZUMA-7: Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, examining second-line therapy for relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care. These findings were presented at the...
Philip L. McCarthy, MD, Comments on Trials Evaluating the Early Detection of Myeloma
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
Studies Evaluate Screening for Early Multiple Myeloma
Precursors to multiple myeloma were identified by population screening in two studies reported at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. The prevalence of monoclonal gammopathies was determined in the PROMISE trial using cutting-edge technology in a high-risk ...
Report Examines Online Learning for Children With Cancer During the COVID-19 Pandemic
Thousands of schools transitioned to online learning in 2020 due to the COVID-19 pandemic, during which time many children with cancer faced significant challenges with their schooling. An opinion paper by Johns Hopkins experts, published by Thornton et al in JAMA Pediatrics, highlights some of the ...
PANTHER: No Significant Benefit for Pevonedistat Plus Azacitidine in Higher-Risk Myelodysplastic Syndrome
The phase III PANTHER trial, which evaluated pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low–blast count acute myeloid leukemia (AML), failed to meet its primary endpoint of event-free survival, though lessons...
Anthracycline Plus Taxane Reduces Risk of Breast Cancer Recurrence at 10 Years
In a large patient-level meta-analysis of 16 trials, presented at the 2021 San Antonio Breast Cancer Symposium (SABCS),1 the combination of an anthracycline plus a taxane achieved a substantial 15% reduction in breast cancer recurrence at 10 years vs taxane chemotherapy alone, representing an...
Clinical Score May Assist in Guiding Peptide Receptor Radionuclide Therapy Decisions for Patients With Neuroendocrine Tumors
Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (Lu-177) dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but clinicians have lacked a metric for predicting its benefit on an individual patient basis....
Combination Therapies May Improve Outcomes Due to Independent, Rather Than Synergistic or Additive, Drug Action
Independent drug action—not synergy nor additivity—accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis published by Palmer et al in Clinical Cancer Research....
Recent Study Aims to Improve the Quality of Cancer Care in Rural Areas
Despite growing national awareness of health-care inequities, cancer care for many rural Americans remains inadequate. To shed some light on the challenges faced by patients with cancer in rural areas, The ASCO Post spoke with Mary Charlton, PhD, Associate Professor of Epidemiology in the...
Durvalumab Plus Gemcitabine/Cisplatin Improves Survival in Patients With Advanced Biliary Tract Cancer: TOPAZ-1
Biliary tract cancer is a rare and often fatal disease comprised primarily of bile duct and gallbladder cancers; it is diagnosed in about 12,000 individuals each year in the United States. The cancer has a 5-year relative survival rate of 25% for localized intrahepatic bile duct cancers and just...
PI3K Pathway Activation May Underlie Tamoxifen-Associated Uterine Cancer
Even though it is infrequent, uterine cancer can develop in patients treated with tamoxifen. A study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) suggests that the mechanism by which uterine cancers develop is tamoxifen-induced PI3K pathway activation.1 Patients treated with...
UICC to Launch 3-Year Campaign to Create More Equitable Access to Cancer Services
On February 4, 2022, the Union for International Cancer Control (UICC) will launch a new 3-year campaign for World Cancer Day that brings together individuals, organizations, and governments around the world in an effort to create awareness and help close the gap in cancer care. The campaign...
New Study Examines Genetic Effects on Genitourinary Toxicity in Patients With Prostate Cancer
Although radiation can be an effective therapy for prostate cancer, about one in six men will experience more frequent or painful urination as a lingering side effect. These disruptive genitourinary toxicities can occur whether the patient receives conventionally fractionated radiotherapy or...
Durvalumab/Tremelimumab With or Without Radiotherapy in Resistant NSCLC
In a recent phase II clinical trial, the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab curtailed tumor growth in some patients with non–small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent. The addition of radiation therapy to the...
Expert Point of View: Anne Blaes, MD, MS, and Virginia Kaklamani, MD
Commenting on the update of RxPONDER presented at the 2021 San Antonio Breast Cancer Symposium were Anne Blaes, MD, MS, Associate Professor of Hematology/Oncology at the University of Minnesota and Co-Director of the Screening, Prevention, Etiology and Cancer Survivorship Program at the Masonic...
RxPONDER Update Explores Benefit of Chemotherapy in Subgroups
Updated results of the SWOG S1007 RxPONDER trial confirmed the key takeaway from the previous analysis: adjuvant chemotherapy benefits premenopausal women but not postmenopausal women with hormone receptor–positive, HER2-negative disease, one to three positive lymph nodes, and a 21-gene Oncotype DX ...
Study Finds Improved 2-Year Survival Rate for Adult Patients With Relapsed Philadelphia Chromosome–Positive ALL After Allogeneic Hematopoietic Cell Transplantation Over 20 Years
A retrospective, registry-based multicenter study by Bazarbachi et al published in Clinical Cancer Research evaluated clinical outcomes in patients with relapsed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic cell transplantation over a...
Educational Intervention Increases Knowledge About Prostate Cancer and Intention to Screen Among High-Risk Patients
In a study published by Charnita Zeigler-Johnson, PhD, MPH, and colleagues in the Journal of Racial and Ethnic Health Disparities, gathering men at high risk for developing prostate cancer for discussion about prostate cancer or other health concerns increased their knowledge about prostate cancer...
Global Burden of Cancer From 2010 to 2019
In an analysis reported in JAMA Oncology, researchers in the Global Burden of Disease 2019 Cancer Collaboration found a global increase in new cases of cancer, cancer deaths, and cancer-related disability-adjusted life-years (DALYs) between 2010 and 2019, with aspects of cancer burden differing...
Report Describes Identification of a Novel Therapeutic Target for Multiple Myeloma
Proteasome inhibitors, the therapeutic backbone of current treatments for multiple myeloma, are effective in treating newly diagnosed disease, but resistance or intolerance to these molecules often develops, leading to relapse. While studying a neglected tropical disease, Buruli ulcer, researchers...
ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers
A clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external-beam radiation therapy (EBRT). Evidence-based recommendations outline indications and optimal EBRT...
Expert Point of View: Ciara O’Sullivan, MB, BCh, BAO
Invited discussant Ciara O’Sullivan, MB, BCh, BAO, of Mayo Clinic, Rochester, Minnesota, commented on the DESTINY-Breast03 trial at the 2021 San Antonio Breast Cancer Symposium. “The treatment of HER2-positive disease is an evolving landscape, with eight approved agents. Despite this rapid...
Role of Radiologist Experience and Fatigue Level in Recommending Additional Imaging for Patients Undergoing Breast Cancer Screening
Less experienced radiologists are more likely to recommend additional imaging for women undergoing breast cancer screening when they read digital breast tomosynthesis (DBT) images later in the day, according to a new study published by Bernstein et al in the journal Radiology. The results highlight ...
Incidence of Chronic Graft-vs-Host Disease: Effect of Depleting Naive T Cells From Peripheral Blood Stem Cell Allografts in Patients With Leukemia
Although allogeneic hematopoietic cell transplantation can result in a cure for patients with advanced hematologic malignancies, studies show chronic graft-vs-host disease occurs in 30% to 60% of patients receiving unmanipulated grafts, often requires prolonged immunosuppression, and may cause...
Developing a Comprehensive System for Personalized Survivorship-Centered Care Plans
By 2040, the number of cancer survivors in the United States is expected to climb from 17 million today to 26.1 million, with most living 5 years or more after their diagnosis. However, many of these survivors will need ongoing monitoring for treatment-related side effects and cancer recurrence...
Study Examines Role of Psychological Distress in AYA Cancer Survivors
New research indicates that psychological distress from cancer and its treatment can cause many adolescent and young adult (AYA) cancer survivors to seek additional care and burden them with considerable medical expenses. The findings were published by Abdelhadi et al in the journal Cancer....
Response-Adapted Omission of Radiotherapy and Comparison of Consolidation Therapy in Pediatric Classical Hodgkin Lymphoma
In analyses from the European EuroNet-PHL-C1 study reported in The Lancet Oncology, Mauz-Körholz et al found that radiotherapy could be omitted in pediatric patients with intermediate- or advanced-stage classical Hodgkin lymphoma who had adequate response to induction with OEPA (vincristine,...
Single-Cell Transcriptomic and Imaging Atlas of Colorectal Polyps Provides Insights for Cancer Surveillance
A team of researchers has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the disease. Their study, published by Chen et al in the journal Cell, describes findings using a single-cell transcriptomic and imaging...
Does Geography Play a Role in Early-Onset Colorectal Cancer in Young Black Men?
Although the incidence and mortality rates in colorectal cancer have dropped by 3.6% each year from 2007 to 2016 for people aged 55 and older—mainly because of increased colorectal cancer screening, advances in therapy, and reductions in smoking—these rates have increased by 2% each year during the ...
